STUDIES OF THYROID DISEASES

甲状腺疾病的研究

• 批准号: 2342197
• 负责人: J ROBBINS
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/2342197
• 关键词: Commonwealth of Independent States; clinical research; combination cancer therapy; dosage; doxorubicin; drug adverse effect; erythrocytes; glycophorin; hormone therapy; human data; human subject; human therapy evaluation; human tissue; iodine; neoplasm /cancer chemotherapy; neoplasm /cancer epidemiology; neoplasm /cancer radionuclide therapy; neoplasm /cancer relapse /recurrence; radiation dosage; radiation hazard; radiosensitizer; recombinant proteins; thyroglobulin; thyroid neoplasm; thyrotropin; whole body radionuclide scanning

Dr. Robbins participates in the NCI/DOE project to study the thyroid effects of the nuclear power reactor accident in Chernobyl. The case- control study in Belarus has been completed and submitted for publication. The results clearly indicate that thyroid cancer cases have a higher thyroid radiation dose than controls matched for age, sex and route to diagnosis. The odds ratio is approximately six. Planning continues for the establishment of prospective cohort studies in Belarus and Ukraine to determine the risk coefficient for thyroid cancer development after exposure to radioiodines. Dr. Robbins participates with the NIH component of the interinstitutional Phase III evaluation of recombinant human TSH (rhTSH) for use in the management of patients treated for thyroid cancer. Initial findings, submitted for publication, indicate that rhTSH is effective in stimulating radioiodine uptake in tumor remnants or metastases while the patient remains euthyroid on thyroid hormone replacement. Current studies are investigating the effects of different dose schedules on the ability of rhTSH to induce tumor uptake as well as to induce an increase in serum thyroglobulin concentration, as required by the Food and Drug Administration prior to approval of the drug for clinical use.

罗宾斯博士参加了NCI/DOE项目，研究甲状腺 切尔诺贝利核反应堆事故的影响。 这案子- 白俄罗斯的控制研究已经完成，并提交给 出版物 结果清楚地表明，甲状腺癌病例 甲状腺辐射剂量高于年龄匹配的对照组， 性别和诊断途径。 优势比大约是6。 继续规划建立前瞻性队列研究 在白俄罗斯和乌克兰， 暴露于放射性碘后的癌症发展。 博士罗宾斯参与了美国国立卫生研究院的组成部分， 重组人促甲状腺激素的机构间III期评价 （rhTSH）用于管理接受甲状腺治疗的患者 癌 提交出版的初步调查结果表明， rhTSH可有效促进肿瘤残留物的放射性碘摄取 或转移，而患者甲状腺激素保持正常 更换. 目前的研究正在调查 不同给药方案对rhTSH致瘤能力的影响 摄取以及诱导血清甲状腺球蛋白增加 根据食品和药物管理局的要求， 药物临床使用的批准。